Miller & Martin Represents Mayne Pharma in Acquisition & U.S. Private Offering
February 16, 2015
On February 10, 2015, Mayne Pharma announced an agreement to acquire the Doryx® brand and related assets in the United States for $50 million from its distribution partner, Actavis. The deal is expected to close in late February. The acquisition will be funded by a fully underwritten $115 million equity raising through a public offering in Australia and private offering here in the U.S.
The Miller & Martin team representing Mayne Pharma in the acquisition and U.S. private offering includes Joe DeLisle, Ashley Halfman, Jonathan Edwards, Jim Tramonte, Billy Eiselstein, Jimmy Daniel, Charles Forlidas, Lis Koehnemann, Michael Marshall, John Henry, Ned Boehm and Bruce McCall. Minter Ellison represented Mayne Pharma in the Australian public offering. Miller & Martin and Minter Ellison are both members of the World Law Group, an exclusive network of 52 law firms in 65 countries. Miller & Martin was first introduced to Mayne Pharma by Minter Ellison in 2012, to represent the company in the acquisition of Metrics, Inc., a pharmaceuticals company based in North Carolina.
Doryx® competes in the U.S. oral antibiotic acne market and is distributed by Actavis plc.
Mayne Pharma is a specialty pharmaceutical company that develops and manufactures branded and generic products. Mayne Pharma distributes these products globally and operates two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, North Carolina, USA.